Evidence map›Paper›PMID 39013374›Full record

Trial reportThe American journal of tropical medicine and hygiene2024

Effect of Adding a Six-Week Course of Doxycycline to Intensive Hygiene-Based Care for Improving Lymphedema in a Rural Setting of Mali: A Double-Blind, Randomized Controlled 24-Month Trial.

Yaya I Coulibaly, Abdoul F Diabate, Moussa Sangare, Sekou O Thera, Housseini Dolo, Salif S Doumbia, Siaka Y Coulibaly, Ayouba Diarra, Lamine Diarra, Diadje Tanapo and 18 more

Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in The American journal of tropical medicine and hygiene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Narrowing the Gap in Managing the Lymphedema of Lymphatic Filariasis.The American journal of tropical medicine and hygiene · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Yaya I CoulibalyInternational Center for Excellence in Research, Bamako, Mali.
Abdoul F DiabateInternational Center for Excellence in Research, Bamako, Mali.
Moussa SangareInternational Center for Excellence in Research, Bamako, Mali.
Sekou O TheraInternational Center for Excellence in Research, Bamako, Mali.
Housseini DoloInternational Center for Excellence in Research, Bamako, Mali.
Salif S DoumbiaInternational Center for Excellence in Research, Bamako, Mali.
Siaka Y CoulibalyInternational Center for Excellence in Research, Bamako, Mali.
Ayouba DiarraInternational Center for Excellence in Research, Bamako, Mali.
Lamine DiarraInternational Center for Excellence in Research, Bamako, Mali.
Diadje TanapoInternational Center for Excellence in Research, Bamako, Mali.
Michel E CoulibalyInternational Center for Excellence in Research, Bamako, Mali.
Lamine SoumaoroInternational Center for Excellence in Research, Bamako, Mali.
Abdallah A DialloInternational Center for Excellence in Research, Bamako, Mali.
Amatigue ZeguimeInternational Center for Excellence in Research, Bamako, Mali.
Yacouba SanogoInternational Center for Excellence in Research, Bamako, Mali.
Adama BertheInternational Center for Excellence in Research, Bamako, Mali.
Fatoumata Dite Nene KonipoInternational Center for Excellence in Research, Bamako, Mali.
Charles MackenzieNeglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia.
Mariana StephensNeglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia.
Joseph P ShottDivision of Neglected Tropical Diseases, Global Health Bureau, Bethesda, Maryland.
Jayla NormanNeglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia.
Ute Klarmann-SchulzInstitute for Medical Microbiology, Immunology and Parasitology, German Centre for Infection Research (DZIF), Bonn-Cologne Site, University Hospital Bonn, Bonn, Germany.
Achim HoeraufInstitute for Medical Microbiology, Immunology and Parasitology, German Centre for Infection Research (DZIF), Bonn-Cologne Site, University Hospital Bonn, Bonn, Germany.
Andrew MajewskiNeglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia.
John HortonTropical Projects, Hitchin, United Kingdom.
Sarah SullivanNeglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia.
Eric A OttesenNeglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia.
Thomas B NutmanNational Institute of Allergy and Infectious Diseases, Bethesda, Maryland.

Funding

Mali International Center for Excellence in Research: FilariasisZIAAI001063 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NUTMAN, THOMAS · 2009 to 2025
$3.2M
6 · The paper itself

Abstract

Lymphedema (LE) is one the most disfiguring chronic manifestations of lymphatic filariasis. Its management relies primarily on limb hygiene and local care. A previous study in Ghana demonstrating a beneficial effect of doxycycline on LE led to the current multicenter trial on the efficacy of doxycycline in filarial LE. A randomized placebo-controlled trial was initiated in two rural health districts in Mali. Patients with LE stages 1-3 were randomized to receive either doxycycline (200 mg/day) or placebo over a 6-week monitored treatment period and were then followed every 6 months for 2 years. Both groups received materials for limb hygiene that was carried out daily for the entire 2-year study. The primary endpoint was lack of progression in LE stage at 24 months. One hundred patients were enrolled in each study arm. The baseline sociodemographic characteristics of each group were largely similar. There was no significant difference at month 24 after treatment initiation in the number of subjects showing progression in LE stage between the two treatment arms (P = 0.5921). Importantly, however, the number of attacks of acute adenolymphangitis (ADLA) was reduced in both arms, but there was no significant difference between the two groups at any follow-up time point (all P >0.23). Doxycycline was well tolerated in those receiving the drug. When added to daily self-administered limb hygiene, a 6-week course of doxycycline (200 mg) was not superior to placebo in increasing the improvement associated with hygiene alone in LE volume, stage, or frequency of ADLA attacks over a 24-month period.

Indexed as

DoxycyclineHygieneLymphedemaRural PopulationAdultDouble-Blind MethodElephantiasis, FilarialFemaleHumansMaleMaliMiddle AgedTreatment OutcomeDoxycycline

Identifiers

PMID39013374
PMCPMC11448486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.